Pharmacist Influence in Buprenorphine Treatment Outcomes for Opioid Dependence

John R Tomko,V. Giannetti

DOI: https://doi.org/10.1345/aph.1H108

2007-01-01

Abstract:Pharmacist Influence in Buprenorphine Treatment Outcomes for Opioid Dependence TOTHE EDITOR: Treatment of opioid dependence with agonist-type agents is a relatively new practice for community-basedpharmacists. Buprenorphine and buprenorphine/naloxone sublingual tabletsare Food and DrugAdministration-approved agonist-type agentsthat are usedfor the treatmentor detoxificationof the opioid-dependent patient. Since treatmentof chemicaldependence with theseagents is becomingmore commonin the outpatient setting,pharmacists mustbe equallyprepared to counselthesepatients as in otherchronicdiseases. Wereportthe resultsof an exploratory quasi-experimental study that examined the impactof differingpharmacist-patient counseling techniqueson abstinence and treatmentretentionin opioid-dependentsubjects in urban andruralbuprenorphine provider physician settings. Methods. The studywas approved by the Duquesne University InstitutionalReviewBoardlHuman SubjectsResearchCommitteeafter full boardreview. Forty-two subjects wereenrolled. Subjects enrolledin the control cohort(n = 20) werecounseled regarding theirmedication therapy at thefirstvisit.Experimental cohortsubjects (n=22)werecounseled regarding theirmedication therapy withadditional dialogue encouraging participation in nonpharmacologic treatmentof chemicaldependence. The dialogue was guidedwith the use of an algorithm that providedthe pharmacist with prompting lines of questions.This questioning reinforced the importance of involvement in lifestylechangeand nonpharmacologic treatment, suchas supportgroupattendance and drugrehabilitationparticipation. Repeatedinteractions witheach experimental subject at subsequentvisits encouraged the developmentof a therapeutic alliance. Results. Demographics betweengroups and overall were similar to those of previouslyreported studies and clinical trials.J•3 Four experimental and 5 control subjects completing the 90 day enrollment remained abstinent and in treatment. Relapse rates of experimental and control cohorts were 81.8% and 75.0%. respectively.No significance wasfoundin pharmacist influence uponrelapse to opioidabuse.Therate of buprenorphine treatmentrechallengeamong relapsingsubjectswas higherin the experimental group(10; 45.5%)than in the controlgroup (4; 20.0%). Including subjects whocompleted the enrollment periodabstinent,as wellas thosewhoreturnedandcompleted treatment following one relapse, overall abstinencerates yielded 13experimentalsubjects (59.1 %) versus8 controlsubjects (40.0%). Despitethe lackof statistical significance, the trendtowardexperimental subject willingness to rechallenge treatmentfollowingrelapse and remain abstinentmay be due to therapeutic alliance formation and reinforcement of adjunctive nonpharmacologic treatmentas emphasizedin the algorithm. Both the development of a therapeutic allianceand reinforcement of nonpharmacologic adjunctive therapyhave beenfoundto be important influences on abstinenceinotherstudies of addiction andas described in a personal communication (Daniel AlfordMD MPH,Assistant Professor, BostonUniversity Schoolof Medicine, BostonMedical Center,andColleenlaBelle RN, Nurse Program Manager. Office Based Opioid Treatment Program, BostonMedical Center.2004Sept 14).4,$ The trend towardpositiveabstinenceand treatmentretentionrates is leading us to further studythiscounseling technique in a larger,communitypharmacy population. Withthe development of medications thatare dispensed in community pharmacies to assist individuals withaddiction disorders, pharmacist reinforcement maybe an effective tool in an overall abstinence program. In addition, a survey is beingdeveloped thatwill assesspharmacist attitudes, beliefs, and knowledge deficits in the areaof opioiddependence. Results of this surveywillbe used to guidecurricular decisions and aid in the development of pharmacist practitioner educational programs.